Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Exp Neurol. 2013 Jan 31;0:56–68. doi: 10.1016/j.expneurol.2013.01.027

Figure 1. Molecular heterogeneity in GBM and medulloblastoma.

Figure 1

Representative H&E stained sections of GBM from two different patients demonstrate similar histologic features (A,C) despite distinct molecular profiles. Tumor in (A) is IDH1R132H mutant (B) while tumor in (C) is negative for the mutation (D) based on immunoreactivity with an antibody directed against the R132H epitope (H09). In addition, tumor in (A) is negative and tumor in (B) is positive for amplification of EGFR by FISH (data not shown). H&E stained sections of medulloblastoma can also appear similar on H&E (E,H) despite prominent molecular differences. Tumor in (E) has upregulation of GAB1 (F) suggesting activity of the SHH signaling pathway and the tumor in (H) exhibits prominent nuclear immunoreactivity for B-catenin (J) suggesting activation of the WNT signaling pathway. Magnification 400×.